Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 8/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL530116 | 0.81 | FTO (0.36) | FTOHPGDMEN1MAPTCYP2C19 | |
| SCHEMBL11303380 | 0.78 | FTO (0.36) | FTOHPGDMEN1MAPTCYP2C19 | |
| SCHEMBL332302 | 0.73 | FTO (0.36) | FTO | |
| SCHEMBL315867 | 0.71 | FTO (0.45) | FTOHPGDMEN1MAPTCYP2C19 | |
| SCHEMBL29871701 | 0.70 | FTO (0.79) | FTOHPGDMEN1MAPTCYP2C19 | |
| SCHEMBL4173117 | 0.70 | FTO (0.79) | FTOHPGDMEN1MAPTCYP2C19 | |
| SCHEMBL2483039 | 0.69 | FTO (0.58) | FTOHPGDMEN1MAPTCYP2C19 | |
| SCHEMBL1463198 | 0.68 | SMAD3 (0.56) | FTOHPGDMEN1MAPTCYP2C19 | |
| SCHEMBL147188 | 0.68 | FTO (0.33) | FTO | |
| SCHEMBL3747895 | 0.66 | FTO (0.35) | FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753371-B2 | Disulfiram derivatives as ALDH1A1 and MAGL inhibitors | BATTERJEE MEDICAL COLLEGE (SA) | 2023-09-12 | — | — | US | disclosed |
| US-20230174474-A1 | DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS | BATTERJEE MEDICAL COLLEGE (SA) | 2023-06-08 | — | — | US | disclosed |
| WO-2021262645-A1 | REDOX-RESPONSIVE NANOPARTICLE COMPOSITIONS FOR OCULAR DELIVERY OF THERAPEUTICS | OHIO STATE INNOVATION FOUNDATION (US) | 2021-12-30 | — | — | WO | disclosed |
| US-9845457-B2 | Maintenance of genomic stability in cultured stem cells | CEDARS-SINAI MEDICAL CENTER (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160108365-A1 | MAINTENANCE OF GENOMIC STABILITY IN CULTURED STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
| US-20160000915-A1 | CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS | IMMUNOMEDICS, INC. | 2016-01-07 | — | — | US | disclosed |
| WO-2014127360-A1 | PCL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-08-21 | — | — | WO | disclosed |
| US-20090325858-A1 | Reduction of Zinc-Induced Neurotoxic Injury By Blockade of Nitric Oxide Synthesis | ANDRO DIAGNOSTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753371-B2 | Disulfiram derivatives as ALDH1A1 and MAGL inhibitors | ALDH1A1, ADH1A, ALDH3A1 | FTO 2106/4885HPGD 569/4885MEN1 2198/4885 |
| US-20230174474-A1 | DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS | ALDH1A1, ADH1A, ALDH3A1 | FTO 2106/4885HPGD 569/4885MEN1 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.